Streetbeat News

Regulatory

RPD

The Schall Law Firm is investigating Rapid7 Inc for potential securities law violations, focusing on possible breaches of fiduciary duty by its directors and management.

Portfolio Pulse from

December 23, 2024 | 3:45 pm

SNPS

EU antitrust regulators are expected to approve Synopsys' $35 billion acquisition of Ansys, contingent on Synopsys selling two assets.

Portfolio Pulse from

December 23, 2024 | 3:30 pm

KROS

Levi & Korsinsky has initiated an investigation into Keros Therapeutics, Inc. for potential federal securities law violations. This follows Keros' announcement of halting certain treatment arms in a clinical trial due to safety concerns.

Portfolio Pulse from

December 23, 2024 | 3:30 pm

BIOA

BioAge Labs (BIOA) has halted its Azelaprag trial, raising concerns about pre-IPO disclosures. Hagens Berman is encouraging investors with significant losses to contact the firm.

Portfolio Pulse from

December 23, 2024 | 3:30 pm

CI

Wendell Potter, former Cigna VP, criticizes the health insurance industry for creating barriers to care, highlighting public dissatisfaction with the sector.

Portfolio Pulse from

December 23, 2024 | 3:00 pm

TSLA

Tesla is recalling nearly 700,000 electric vehicles due to a tire-safety issue. However, the company has already begun implementing a software fix, so owners do not need to take immediate action.

Portfolio Pulse from

December 23, 2024 | 2:45 pm

MDNGF

Midnight Sun Mining Corp has successfully renewed its Large Scale Exploration Licence for the Kazhiba Target, marking a significant milestone in its exploration and development strategy.

Portfolio Pulse from

December 23, 2024 | 2:45 pm

FE

FirstEnergy Pennsylvania has received approval to implement phase three of its Long-Term Infrastructure Improvement Plan (LTIIP), which aims to enhance service reliability through grid modernization and system resiliency.

Portfolio Pulse from

December 23, 2024 | 2:30 pm

ANEB

Anebulo Pharmaceuticals has announced a positive regulatory update for its drug Selonabant, aimed at treating acute cannabis-induced toxicity in children. Additionally, the company has raised capital to support its initiatives.

Portfolio Pulse from

December 23, 2024 | 2:30 pm